Netupitant/palonosetron

From Wikipedia, the free encyclopedia

Netupitant/palonosetron
Combination of
NetupitantNK1 receptor antagonist
Palonosetron5-HT3 receptor antagonist
Clinical data
Trade namesAkynzeo
AHFS/Drugs.comMonograph
MedlinePlusa614053
License data
Pregnancy
category
Routes of
administration		By mouth, intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [2]
  • US: ℞-only [3]
  • EU: Rx-only [4]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
  • 2446322-17-2
KEGG

Netupitant/palonosetron, sold under the brand name Akynzeo, is a fixed-dose combination medication for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[3][6] It is marketed and distributed by . Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[7]

The capsules contain netupitant and palonosetron hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride.[8][3]

Contraindications[]

Netupitant/palonosetron may be contraindicated during pregnancy.[9][1][5]

Adverse effects[]

The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[3] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[9]

Interactions[]

Further information: Netupitant § Interactions, and Palonosetron § Interactions

Pharmacology[]

Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology

History[]

Netupitant/palonosetron was approved for use in the United States in October 2014.[10] It was approved for use in the European Union in May 2015.[4] The intravenous version was approved in the United States in April 2018.[11][8]

References[]

  1. ^ a b c "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 19 March 2020.
  2. ^ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Retrieved 19 March 2020.
  3. ^ a b c d "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Retrieved 18 July 2020.
  4. ^ a b "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Retrieved 19 March 2020.
  5. ^ a b "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Retrieved 19 March 2020.
  6. ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". U.S. Food and Drug Administration (FDA). 10 October 2014. Archived from the original on 1 February 2017. Retrieved 16 December 2019.
  7. ^ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Retrieved 12 July 2016.
  8. ^ a b "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Retrieved 19 March 2020.
  9. ^ a b Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
  10. ^ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Retrieved 19 March 2020.
  11. ^ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Retrieved 19 March 2020.

Further reading[]

External links[]

Retrieved from ""